protein kinase AMP-activated non-catalytic subunit gamma 3Genealiases: AMPKG3 · SMGMQTL
Q-omics provides the consensus-scored PRKAG3 profile across patient tissues and cancer cell-line models. PRKAG3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, PRKAG3 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, PRKAG3 RNA expression shows 14,108 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, LUAD, and UVM as cancer lineages where PRKAG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKAG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKAG3 survival associations across molecular data types. PRKAG3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKAG3 RNA expression–survival associations across cancer types. High PRKAG3 expression shows unfavorable associations in READ, CHOL, HNSC and LAML, but favorable associations in LUAD and BLCA. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify READ as the clearest survival context for PRKAG3 RNA expression.
This table summarizes PRKAG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PRKAG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKAG3 shows lower tumor expression in LUAD, PRAD, UCEC and THCA and higher tumor expression in LIHC and KIRC. The LUAD box plot shows higher PRKAG3 RNA expression in normal versus tumor tissue (log2 FC = −0.100, t-test p < 0.001).
This table shows molecular features associated with PRKAG3 in patient tissues and cancer cell lines. In patient samples, PRKAG3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKAG3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
